Casgevy and Lyfgenia reset a 100,000-patient US market, yet hydroxyurea, proven decades ago, still reaches only 25-30% of eligible patients.

Sickle cell disease became a gene-therapy market in December 2023, when the FDA approved two one-time autologous therapies for patients aged 12 and older with recurrent vaso-occlusive disease. Casgevy (exagamglogene autotemcel, Vertex/CRISPR Therapeutics) uses CRISPR-Cas9 to edit the BCL11A enhancer and reactivate fetal hemoglobin; in the pivotal CLIMB SCD-121 study, 29 of 30 evaluable patients (97%) were free from severe vaso-occlusive crises for at least 12 months. Lyfgenia (lovotibeglogene autotemcel, bluebird bio) adds an anti-sickling beta-globin gene via a lentiviral vector and carries an FDA boxed warning for hematologic malignancy. Both require weeks of myeloablative conditioning and apheresis, and carry one-time list prices of roughly $2.2M and $3.1M.

Against these curative-intent therapies sits a disease-modifying backbone that remains under-deployed. Generic hydroxyurea, proven decades ago to cut painful crises by about 44%, still reaches only 25-30% of eligible patients. L-glutamine (Endari) and the P-selectin inhibitor crizanlizumab (Adakveo) round out the oral and infused options. The field narrowed in 2024 when Pfizer withdrew voxelotor (Oxbryta) from the market over a safety signal: FDA Drugs@FDA now lists it as discontinued, and it is excluded from this in-market landscape. The commercial contest is therefore two-tiered, a high-cost, logistically demanding gene-therapy duel layered over a legacy backbone with a large, addressable adherence gap.

Curative gene therapy costs millions; the cheap generic backbone still reaches a quarter of patients.

Five questions this report answers:

Q1 - How do Casgevy and Lyfgenia differ on mechanism, efficacy, safety, price, and patient eligibility?

Q2 - Why does generic hydroxyurea still reach only 25-30% of eligible SCD patients?

Q3 - Why was voxelotor (Oxbryta) withdrawn from the market in 2024, and what does that leave in the oral field?

Q4 - What do Casgevy's $2.2M and Lyfgenia's $3.1M one-time list prices mean for payer budgeting?

Q5 - What does Lyfgenia's FDA boxed warning for hematologic malignancy mean for prescriber and patient uptake?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SickleCellDisease #US #CompetitiveIntelligence #AXLRx #GeneTherapy #PharmaMarketAccess

Live report page:  https://axlrx.ai/sickle-cell-disease/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-      hello@axlrx.ai

Web-      https://axlrx.ai/